Morpholino

MO1-mmp2

ID
ZDB-MRPHLNO-081029-8
Name
MO1-mmp2
Previous Names
None
Target
Sequence
5' - GTGGCGAACAGCCCTTTCAGACGTG - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
Genomic Features
No data available
Expression
Gene expression in Wild Types + MO1-mmp2
Phenotype
Phenotype resulting from MO1-mmp2
Phenotype of all Fish created by or utilizing MO1-mmp2
Phenotype Fish Conditions Figures
head morphology, abnormal WT + MO1-mmp2 standard conditions text only from Coyle et al., 2008
ventral wall of dorsal aorta hematopoietic multipotent progenitor cell runx1 expression spatial pattern, abnormal WT + MO1-mmp2 control Fig. 2 with image from Theodore et al., 2017
ventral wall of dorsal aorta myb expression increased amount, abnormal WT + MO1-mmp2 control Fig. 5 with image from Theodore et al., 2017
hematopoietic system posterior region myb expression decreased amount, abnormal WT + MO1-mmp2 control Fig. 5 with image from Theodore et al., 2017
ventral wall of dorsal aorta hematopoietic multipotent progenitor cell myb expression spatial pattern, abnormal WT + MO1-mmp2 control Fig. 2 with image from Theodore et al., 2017
mandibular arch skeleton morphology, abnormal WT + MO1-mmp2 standard conditions text only from Coyle et al., 2008
ventral wall of dorsal aorta hematopoietic multipotent progenitor cell GFP expression spatial pattern, abnormal la116Tg + MO1-mmp2 control Fig. 2 with image from Theodore et al., 2017
convergent extension involved in gastrulation disrupted, abnormal WT + MO1-mmp2 + MO1-mmp9 standard conditions Fig. 3 from Coyle et al., 2008
whole organism posterior region has fewer parts of type hematopoietic multipotent progenitor cell, abnormal pd27Tg; zf169Tg + MO1-mmp2 chemical treatment by environment: N(2)-([biphenyl]-4-ylsulfonyl)-N-hydroxy-N(2)-isopropoxy-D-valinamide Fig. 5 with image from Theodore et al., 2017
whole organism anterior region has extra parts of type hematopoietic multipotent progenitor cell, abnormal pd27Tg; zf169Tg + MO1-mmp2 chemical treatment by environment: N(2)-([biphenyl]-4-ylsulfonyl)-N-hydroxy-N(2)-isopropoxy-D-valinamide Fig. 5 with image from Theodore et al., 2017
hematopoietic stem cell migration decreased occurrence, abnormal pd27Tg; zf169Tg + MO1-mmp2 chemical treatment by environment: N(2)-([biphenyl]-4-ylsulfonyl)-N-hydroxy-N(2)-isopropoxy-D-valinamide Fig. 5 with image from Theodore et al., 2017
Citations